Core Viewpoint - AstraZeneca is upgrading its stock listing to replace its American Depositary Receipts (ADRs) on Nasdaq, starting trading on the New York Stock Exchange, reflecting a strategic shift towards the U.S. market, which accounts for nearly half of its revenue [1][3][4] Group 1: Company Strategy - The move aims to equalize AstraZeneca's listing status across the UK, Sweden, and the U.S., highlighting the increasing importance of the U.S. market for the company's business [1][3] - CEO Pascal Soriot's strategy focuses on growth in the largest pharmaceutical market, leading to a relative decrease in reliance on the domestic market [1][4] - AstraZeneca has committed to investing $50 billion in the U.S. by 2030, while pausing a £200 million ($274 million) expansion plan at its UK headquarters due to pressures from U.S. import tax policies [1][4] Group 2: Market Dynamics - The transition allows U.S. investors to purchase AstraZeneca's common stock directly, potentially diminishing the significance of its London listing [1][3] - Peel Hunt's research suggests that the trading focus of AstraZeneca's stock may gradually shift to the U.S. market, with a possibility of relocating its primary listing from London to the U.S. in the long term [4] - The change will exempt investors from paying the UK stock transaction stamp duty, which could result in an annual loss of £200 million in tax revenue for the UK Treasury [4] Group 3: Industry Trends - The trading volume of UK companies' ADRs has surged, with a reported increase of over 80% for 20 companies in the FTSE 100 index from 2019 to 2024 [2][5] - AstraZeneca's ADR trading volume rose by 34% over the same period, while its London market stock trading volume increased by less than 8% [5] - The U.S. market is characterized by larger scale and stronger liquidity, attracting high-growth companies, while the UK market is often seen as undervalued and dominated by traditional economic sectors [5]

Core Viewpoint - The article discusses the differences between direct investment in U.S. common stocks and indirect investment through American Depositary Receipts (ADRs), highlighting the significance of understanding these differences for investors. Group 1: Differences in Issuance and Ownership - U.S. common stocks are issued directly by U.S. or foreign companies to investors, representing direct ownership, while ADRs are issued by U.S. depositary banks and represent shares of foreign companies, leading to indirect ownership [1]. - Common stocks are listed on U.S. exchanges like the NYSE or NASDAQ, whereas ADRs are traded on U.S. exchanges but are based on foreign stocks [1]. Group 2: Transaction Costs and Mechanisms - Investors in U.S. common stocks incur standard transaction costs such as commissions and regulatory fees, while ADRs may involve additional fees from depositary banks, including deposit service fees and dividend conversion fees [2]. - ADRs are categorized into different levels (Level 1, Level 2, Level 3), each with varying trading scopes and disclosure requirements, unlike common stocks which do not have such classifications [2]. Group 3: Shareholder Rights - Shareholders of U.S. common stocks can directly exercise their voting and dividend rights, while ADR holders must go through depositary banks to exercise these rights, making the process more complex [2]. Group 4: Regulatory and Disclosure Requirements - U.S. common stocks are subject to strict regulations by the SEC and must disclose financial reports according to GAAP, while ADRs must comply with both U.S. regulations and those of their home countries [3]. - Disclosure requirements for ADRs vary by level, with Level 3 ADRs needing to submit comprehensive reports similar to U.S. companies, while Level 1 ADRs have simplified disclosure requirements [3]. Group 5: Liquidity Performance - The liquidity of U.S. common stocks is determined by their market activity, with larger companies typically having better liquidity [3]. - The liquidity of ADRs depends on the market recognition, size, and trading demand of the corresponding foreign companies, with some leading companies' ADRs having liquidity comparable to common stocks, while smaller companies' ADRs may have lower liquidity [3].

Core Viewpoint - SK Hynix, an artificial intelligence memory chip manufacturer, is evaluating the possibility of listing in New York to narrow the valuation gap with U.S. peers like Micron Technology [1] Group 1 - The company has submitted a document to regulators indicating it is assessing various measures to enhance corporate value, including the potential use of treasury stock for a U.S. stock market listing [1] - Reports from the Korea Economic Daily suggest that SK Hynix has received proposals from several investment banks to list approximately 2.4% of its issued shares (around 17.4 million shares) in the form of American Depositary Receipts [1]